How many investments has BioRock Ventures made?

BioRock Ventures has 6 tracked investments, 2 of which have exited, including 1 dated in the last 24 months.

What stage does BioRock Ventures invest at?

BioRock Ventures invests at the Pre-Seed, Seed, Series A, Late Stage stages.

What sectors does BioRock Ventures focus on?

BioRock Ventures focuses on Biotech, Healthtech, Medical Devices.

Where is BioRock Ventures located?

BioRock Ventures is headquartered in San Francisco, US.

Who does BioRock Ventures co-invest with?

BioRock Ventures most often shares deals with BioBrit, RA Capital, Breakout Ventures, among 16 tracked co-investors.

BioRock Ventures

Venture capitalActively deployingoperating company · company profile

San Francisco · Pre-Seed–Late Stage · 1 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into BioRock Ventures

234 people in our graph share verified history with the BioRock Ventures team — schools, employers, funds. One of them is your warm intro.

Karthik Ardhanareeswaranunlockedknows Mary Wheeler · together at Johnson & Johnson (overlapped)

×6knows the team · via Kauffman Fellows Program

×4knows the team · via AngelList

knows the team · via Johnson & Johnson

✨ Fox Verdict

Investment thesis

BioRock Ventures focuses on seed-sized investments into private life science companies building best-in-class, FDA-regulated therapeutic drugs. The fund invests across all disease areas, all stages, and all therapeutic modalities, participating from angel and seed through Series A and up to pre-IPO or M&A exits.

Invests inBiotech Healthtech Medical Devices Palo Alto San Francisco San Francisco Bay Area United States

Source: firm website, verified Aug 7, 2026.

Stage

Pre-Seed–Late Stage

San Francisco, California, US

Instruments

Equity

Founded

2019

Last 12 months

1 investment

Tracked investments

IPOs

Team · 1 people

from the firm's website

Mary Wheeler· Managing Director· Bay Area, CAin

Founding managing partner of BioRock Ventures with two decades of therapeutics operating experience, beginning as a startup founder in Boston and later leading M&A, licensing, and strategy at pharmaceutical companies including Johnson & Johnson and Forest (now Allergan/AbbVie). She has consulted as CBO for dozens of early-stage ventures and, over the past decade, helped seed two companies that each achieved IPO exits valued over $1 billion. She is a Kauffman Fellow with an MBA from MIT Sloan, a PhD from Princeton, and an undergraduate degree from Yale.

m•••@biorockventures.comreveal

What they invest in

from 5 of 6 portfolio companies

Biotech ×5Healthtech ×4Deep Tech ×1Medical Devices ×1

HQs:United States×4

Investments · 6 tracked

founders shown can be your intro path

AN2 Therapeuticsan2therapeutics.com inNASDAQ: ANTXMar 2026

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.

BiotechHealthtechMenlo Park, US

Joseph S. Zakrzewski(Co-Founder & Director)Eric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)Sanjay Chanda(Chief Development Officer)in Lucy O. Day(Chief Financial Officer)in

Co-investorsAdjuvant Capital Flucas Ventures Mountain Group Capital RA Capital Biotechnology Value Fund Hatteras Venture Partners

Vaxcytevaxcyte.comNASDAQ: PCVX

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

Grant Pickering(Founder)in Grant E. Pickering(Chief Executive Officer and Director)in

Partner Mary Wheeler· solo GP

Co-investorsCTI Life Sciences Fund L.P.Foresite Capital Frazier Life Sciences Longitude Capital RA Capital Janus Henderson Investors +2 more

Immusoftimmusoft.com

Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.

BiotechDeep TechHealthtechSeattle, US

Matthew Scholz(Founder)in Sean Ainsworth(Chief Executive Officer)inRobert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)inScott McIvor(Chief Development Officer)Eric Garcia(Executive Officer)in

Co-investorsBoston Harbor Angels Breakout Ventures EQx Fund Invariantes Fund Michigan Capital Network NYBC Ventures +1 more

Primmune Therapeuticsprimmunerx.com in 𝕏

Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.

BiotechHealthtechCarlsbad, US

James Appleman(SVP, R&D and CSO, Cofounder)Paulo Rangel(Chief Business Officer and Cofounder)inStephen Webber(Vice President, Medicinal Chemistry, and Cofounder)inCharles McDermott(President & CEO, Director)

BoardTodd J Harris(Director)in

Co-investorsBioBrit Samsara BioCapital Bioqube Ventures Oberland Capital Polaris Partners

PTM Therapeutics, Inc.ptmthera.com

PTM Therapeutics is a biotechnology company developing therapeutic candidates.

BiotechMedical DevicesBedford, US

Jennifer C. Cheng(CEO/Co-Founder)Tony W. Liang(VP of Research/Co-Founder)inCharles A. Parkos(Scientific Co-Founder)Jennifer C. Brazil(Scientific Co-Founder)

Co-investorsBioBrit

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

AN2

Exits · 2

2 IPOs

AN2 TherapeuticsNASDAQ: ANTXVaxcyteNASDAQ: PCVX

Portfolio news

latest coverage across their companies

Vaxcyte at Cantor conference: broad vaccine bet nears key test By Investing.com

Vaxcyte · uk.investing.com · Sep 9, 2026

An2 Therapeutics director Robin Readnour sells $212,701 in common stock By Investing.com

AN2 Therapeutics · ng.investing.com · Aug 19, 2026

Sell or Invest in Primmune Therapeutics Stock Pre-IPO

Primmune Therapeutics · nasdaqprivatemarket.com · Apr 3, 2026

Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine - Immusoft

Immusoft · immusoft.com · Mar 30, 2026

Frequently asked questions

How many investments has BioRock Ventures made?: BioRock Ventures has 6 tracked investments, 2 of which have exited, including 1 dated in the last 24 months.
What stage does BioRock Ventures invest at?: BioRock Ventures invests at the Pre-Seed, Seed, Series A, Late Stage stages.
What sectors does BioRock Ventures focus on?: BioRock Ventures focuses on Biotech, Healthtech, Medical Devices.
Where is BioRock Ventures located?: BioRock Ventures is headquartered in San Francisco, US.
Who does BioRock Ventures co-invest with?: BioRock Ventures most often shares deals with BioBrit, RA Capital, Breakout Ventures, among 16 tracked co-investors.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Illumina Ventures

Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.

Novartis Venture Fund

The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.

$5M – $25M